Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
TG Therapeutics Investigational Trial Site, La Jolla, California TG Therapeutics Investigational Trial Site, Lexington, Kentucky TG Therapeutics Investigational Trial Site, Ann Arbor, Michigan TG Therapeutics Investigational Trial Site, Omaha, Nebraska TG Therapeutics Investigational Trial Site, New York, New York TG Therapeutics Investigational Trial Site, Rochester, New York TG Therapeutics Investigational Trial Site, Cleveland, Ohio TG Therapeutics Investigational Trial Site, Columbus, Ohio TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin